Alterity Therapeutics recognizes MSA Awareness Month

Alterity Therapeutics (ATHE) recognizes Multiple System Atrophy, MSA, Awareness Month this March and the importance of raising awareness for a rare neurological disorder with no approved treatment options. “MSA Awareness Month is an important opportunity to recognize the resilience of patients and care partners living with this devastating condition and to highlight the urgent need for therapies that can change the course of disease,” said David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics. “At Alterity, we are committed to advancing research that targets the underlying pathology of MSA and are very encouraged by our data that demonstrate the potential of ATH434 as a disease-modifying therapy.”